Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ555MR)

This product GTTS-WQ555MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Gastric Cancer, Breast Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ555MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13362MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ896MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ10717MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ4288MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ1041MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ12524MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ5831MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ11292MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-522
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW